lapatinib
1 product
13 abstracts
Abstract
Preliminary safety and efficacy of TQB2930, a HER2-targeted bispecific antibody in patients with advanced breast cancer: Results from a phase 1b study.Org: Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China, Harbin Medical University Cancer Hospital, Harbin, China, Chongqing University Cancer Hospital, Chonqqing, China, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing, China, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center,
Abstract
Efficacy and safety of pyrotinib combined with trastuzumab emtansine (T-DM1) for patients with advanced HER2-positive breast cancer (BC): A single-arm phase II trial.Org: Tianjin Cancer Hospital Airport Hospital,
Abstract
ACE-Breast-02: A pivotal phase II/III trial of ARX788, a novel anti-HER2 antibody-drug conjugate (ADC), versus lapatinib plus capecitabine for HER2+ advanced breast cancer (ABC).Org: Hospital of Xinjiang Production and Construction Corps,
Abstract
A phase Ia/b trial of ARX788 combined with toripalimab for HER2-low advanced breast cancer (ABC) and other HER2-expressing solid tumors.Org: Department of Breast Medical Oncology, Fujian Cancer Hospital, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China, Center of Hepato-Pancreato-Biliary Surgery, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, First Affiliated Hospital of Wannan Medical College, Sun Yat-sen University Cancer Center Gansu Hospital,
Abstract
Association between stromal tumor-infiltrating lymphocytes (TILs) and pathologic complete response (pCR) in patients with early breast cancer (BC) treated with neoadjuvant chemotherapy and HER2-directed therapies in NSABP B-41.Org: NSABP/NRG Oncology and the UPMC Hillman Cancer Center,
Abstract
T-DM1 in Chinese patients with Her2-positive metastatic breast cancer: A multi-center, retrospective, real world study.Org: National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Shougang Beijing University Hospital,
Abstract
A systematic review and meta-analysis of intrathecal versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.Org: Université de Montréal, McGill University Health Center, Department of Medical Oncology, Institut du Cancer de Montpellier, Institut de Génomique fonctionnelle, CNRS, University of MontpellierOncology, Institute of Oncology Ljubljana,
Abstract
Real-world treatment patterns in patients with HER2+ unresectable or metastatic breast cancer: Interim results from HER2 REAL Asia cohort.Org: National University Hospital, National Cheng Kung University Hospital, Queen Elizabeth Hospital, Seoul National University Hospital, Westmead Hospital,
Abstract
Anti-HER2 antibody inetetamab plus camrelizumab and utidelone for pretreated HER2-positive metastatic breast cancer: Final results from the phase 2 ICU trial.Org: Department of Breast Disease, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Breast Medicine Service, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China,
Abstract
Association of HER2/CEP17 ratio with pCR after HER2-directed neoadjuvant treatments in the phase III NeoALTTO trial.Org: Comprehensive Cancer Center - Universitätsklinik für Frauenheilkunde Medizinische Universität Wien / AKH, Medical University of Vienna, Dept of OB/GYN, Karl Landsteiner Medical University, Department of Gynecology and Obstetrics, Medical University of Innsbruck, Innsbruck, Austria, Department of Oncology, Medical University of Graz,
Abstract
Impact of use of CDK4/6i and neratinib among patients with HER2 +ve MBC: Results from a real world dataset.Org: Mediclinic City Hospital, TriNetX Europe,
Abstract
FcεRIγ-negative NK cells and association with improved outcomes in trastuzumab-treated patients.Org: Tempus Labs, Inc., Durham, NC, Statagize LLC, Thousand Oaks, CA, Indapta Therapeutics Inc.,
Abstract
Evolution of breast cancer management in the Dominican Republic in the 21st century.Org: FUNDEONCAP, IOHP, Dominican Society of Oncology,
Product
Lapatinib+Capecitabine